*Division of Molecular Pathology
†Division of Psychosocial research and Epidemiology
‡Department of Surgery
§Department of Pathology, Division of Diagnostic Oncology
∥Core Facility Molecular Pathology and Biobanking, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
L.L.V., F.E.v.L., E.J.R., M.S., M.K.S., E.H.L., and J.W.: designed the study. L.L.V. and L.E.E.: collected the data. D.P., I.H., and A.B.: set up and performed IHC stains. L.L.V., K.v.d.V., E.J.G., M.M.A., J.W., J.S., and C.B.: did the pathology review and IHC assessment. L.L.V., F.E.v.L., E.J.R., M.S., M.K.S., E.H.L., and J.W.: analyzed and interpreted the data. L.L.V.: wrote the report.
Conflicts of Interest and Source of Funding: This work was funded by Pink Ribbon (grant number 2013.WO29, to J.W.) and A Sister’s Hope (grant number 2011.WO19.C88, to J.W.), and it was jointly funded by Cancer Research UK and the Dutch Cancer Society (grant number C38317/A24043, to J.W.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Correspondence: Jelle Wesseling, MD, PhD, Department of Pathology, Division of Diagnostic Oncology and Division of Molecular Pathology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands (e-mail: [email protected]).